Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma-Reference-Cited by-同舟云学术

Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma

Published:2013-08-08 Issue:6 Volume:122 Page:863-871
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Linette Gerald P.¹,Stadtmauer Edward A.²,Maus Marcela V.²,Rapoport Aaron P.³,Levine Bruce L.²,Emery Lyndsey²,Litzky Leslie²,Bagg Adam²,Carreno Beatriz M.¹,Cimino Patrick J.¹,Binder-Scholl Gwendolyn K.⁴,Smethurst Dominic P.⁴,Gerry Andrew B.⁴,Pumphrey Nick J.⁴,Bennett Alan D.⁴,Brewer Joanna E.⁴,Dukes Joseph⁵,Harper Jane⁵,Tayton-Martin Helen K.⁴,Jakobsen Bent K.⁴⁵,Hassan Namir J.⁵,Kalos Michael²,June Carl H.²

Affiliation:

1. Siteman Cancer Center and Departments of Medicine and Pathology and Immunology, Washington University School of Medicine, St. Louis, MO;

2. Abramson Cancer Center, Department of Medicine, and Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA;

3. The Greenebaum Cancer Center, University of Maryland, Baltimore, MD;

4. Adaptimmune Ltd, Philadelphia and Abingdon, United Kingdom; and

5. Immunocore Ltd, Abingdon, United Kingdom

Abstract

Key Points Engineered T-cell receptors can have redundant recognition of alternative protein motifs, resulting in severe cardiac toxicity. The use of induced pleuripotent stem cells (iPSCs) is a promising approach to identify potential off-target effects of engineered T cells.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/122/6/863/1374971/863.pdf

Reference33 articles.

1. T-cell-receptor gene therapy.;Schumacher;Nat Rev Immunol,2002

2. Control of HIV-1 immune escape by CD8 T cells expressing enhanced T-cell receptor.;Varela-Rohena;Nat Med,2008

3. Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1.;Robbins;J Clin Oncol,2011

4. Quantifying and imaging NY-ESO-1/LAGE-1-derived epitopes on tumor cells using high affinity T cell receptors.;Purbhoo;J Immunol,2006

5. Identification of titin as an alternative specificity for engineered T cells expressing an enhanced affinity MAGE A3 TCR.;Cameron;Sci Transl Med

Cited by 897 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Lymph Node–Targeted Vaccine Boosting of TCR T-cell Therapy Enhances Antitumor Function and Eradicates Solid Tumors;Cancer Immunology Research;2024-01-25

2. Mechanical forces amplify TCR mechanotransduction in T cell activation and function;Applied Physics Reviews;2024-01-19

3. Cancer Nano-Immunotherapy: The Novel and Promising Weapon to Fight Cancer;International Journal of Molecular Sciences;2024-01-18

4. TCR-engineered T-cells directed against Ropporin-1 constitute a safe and effective treatment for triple-negative breast cancer in near-clinical models;2024-01-11

5. Preclinical evaluation of a novel CAR-T therapy utilizing a scFv antibody highly specific to MAGE-A4p230-239/HLA-A∗02:01 complex;Molecular Therapy;2024-01